A broader-targeting Cas12f nuclease and its derived gene editing tools

By constructing Cas12f nucleases and their derivatives with a wider targeting range through amino acid mutations of Un1Cas12f1 and the MS2-MCP strategy, the problem of the narrow targeting range of Cas12f nucleases in mammalian cells has been solved, and more efficient gene editing has been achieved.

CN119709700BActive Publication Date: 2026-11-17EAST CHINA NORMAL UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510015341.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-01-06
Publication Date
2026-11-17
Estimated Expiration
2045-01-06

AI Technical Summary

Technical Problem

The existing Cas12f nuclease has a narrow targeting range and low editing efficiency in mammalian cells, which limits its application in the field of gene therapy.

Method used

By performing single-point and combinatorial mutations on Un1Cas12f1 amino acid residues, a Cas12f nuclease with a broader targeting range, Cas12f-SSRSV, was developed. In conjunction with the MS2-MCP strategy, adenosine base editor SSRSV-ABE, cytosine base editor SSRSV-CBE, and transcription activation tool PHM-SSRSV with a broader targeting range were constructed.

Benefits of technology

It improved the targeting range and editing efficiency of Cas12f nuclease, enhanced PAM compatibility, and achieved more efficient gene editing results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119709700B_ABST
    Figure CN119709700B_ABST
Patent Text Reader

Abstract

This invention provides a Cas12f nuclease with a broader targeting range and its derived gene editing tools. The invention successfully developed the Un1Cas12f1 mutant Cas12f-SSRSV, which has a broader targeting range, and evaluated its editing characteristics. Simultaneously, this invention constructed the adenine base editor SSRSV-ABE, the cytosine base editor SSRSV-CBE, and the transcription activation tool PHM-SSRSV, all with broader targeting ranges, using the MS2-MCP strategy. This addresses the AAV packaging limitations while providing more options for target design. The design of this invention stems from the practical needs of gene editing tools in clinical translation, developing smaller nucleases, ABEs, CBEs, and transcription activation tools with higher PAM compatibility, demonstrating significant clinical translational value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of gene editing technology, and in particular to a Cas12f nuclease with a broader targeting range and its derived gene editing tools. Background Technology

[0002] The CRISPR / Cas system and its derivative gene-editing tools have been widely used for human cell genome editing, but commonly used gene-editing tools are limited by their large molecular size, making efficient delivery into the body difficult. The Cas12f family of -F-type nucleases is a class of nucleases discovered in archaea. Compared to Cas9 and Cas12a, they are much smaller, consisting of only 400-700 amino acids. Even when fused with effector proteins such as deaminases and transcription factors, they can be delivered via a single AAV. Besides their small size, Cas12f also exhibits high specificity, low off-target rate, and is less prone to causing large fragment deletions and chromosomal translocations, thus making it a promising candidate for gene therapy. However, Cas12f has low editing activity in mammalian cells, and its PAM sequence is very restrictive, severely limiting its application. Current research on Un1Cas12f1 is relatively comprehensive; its cleavage pattern and crystal structure have been resolved. Un1Cas12f1 recognizes 5'-TTTR-3' (R=A / G) PAM and cleaves both strands almost simultaneously to form sticky ends. It creates a cleavage 24 bp downstream of the target strand PAM and generates random cleavages 20-22 bp downstream of the non-target strand PAM, both of which are located outside the target site. In 2021, Osamu Nureki's team and Chang Leifu's team published papers revealing the cryo-electron microscopy structure of Un1Cas12f1. Both papers found that Un1Cas12f1 functions as a dimer. Two Un1Cas12f1 proteins bind to a single sgRNA in an asymmetric homodimer form, recognizing and cleaving dsDNA.

[0003] Although Un1Cas12f1 has a size advantage, its cleavage activity in mammalian cells is very low, greatly reducing its application value. Previous literature has reported that engineering sgRNA can improve the editing efficiency of Cas9; therefore, modifying sgRNA may also improve the editing efficiency of Un1Cas12f1. Yong-Sam Kim's team identified five potential modification sites (MS1-MS5) in the Un1Cas12f1 sgRNA, ultimately optimizing ge4.1, which shortened the sgRNA from 222 nt to 129 nt. Compared to the original sgRNA, ge4.1's length was reduced by approximately 40%, and the editing efficiency was improved by 867-fold.

[0004] Besides optimizing sgRNA, engineering the Cas protein is also a common optimization strategy. Previous articles have reported that mutations in the amino acids within the DNA-binding pocket can affect DNA binding, thereby improving the editing efficiency of AsCas12a. Qi Lei's team rationally designed Un1Cas12f1 based on its protein structure. By comparing its structure with Cas12a, they selected 28 sites and mutated them to positively charged arginine residues. This strategy may increase the interaction between Un1Cas12f1 and negatively charged DNA and sgRNA. They used a GFP transcription-activated cell line to screen for 28 single-point arginine mutants, and after multiple rounds of optimization, finally developed CasMINI V4, which significantly improved the DNA-binding activity of Un1Cas12f1. Compared to wild-type Un1Cas12f1, CasMINI V4 showed approximately 200-fold increased GFP reporter gene activation efficiency.

[0005] Due to its small size, Un1Cas12f1 can be delivered via a single AAV even when fused with deaminases such as TadA and APOBEC1, or transcriptional regulatory elements such as VP64. Therefore, Un1Cas12f1 has significant potential for application in gene therapy. Qi Lei's team developed the transcriptional activation tool dCasMINI-VPR by fusing the transcriptional activation element VPR with dCasMINI V4. They also fused the adenine deaminase TadA-TadA8e to the N-terminus of dCasMINI V4, developing dCasMINI-ABE. The editing window of dCasMINI-ABE is mainly concentrated at positions A3-A4. Cheng Tianlin's team inserted the TadA deaminase into the middle of dUn1Cas12f1-RRA (D143R, T147R, E151A) and mutated the TadA deaminase to develop Un1Cas12f1-derived miniABEs and miniCBEs. Ma Hanhui's team developed dUn1Cas12f1-3R-VPR by fusing the transcriptional activation element VPR to the C-terminus of dUn1Cas12f1-3R (D143R, T147R, T203R). To further improve transcriptional activation efficiency, they fused the double-stranded DNA binding domain Sso7d to the C-terminus of dUn1Cas12f1-3R-VPR to construct Sso7d-dUn1Cas12f1-3R-VPR-C (SminiCRa), which further increased the activation level by approximately 4-fold. In addition to the transcriptional activation tool, Ma Hanhui's team also replaced VPR with KRAB to develop the transcriptional repression tools miniCRi (dUn1Cas12f1-3R-KRAB) and SminiCRi (dUn1Cas12f1-3R-KRAB-Sso7d).

[0006] However, the aforementioned studies have not addressed the limitation of Cas12f's narrow targeting range, and the editing efficiency of the optimized Cas12f nuclease and its derived editing tools in mammalian cells and animals still lags behind that of traditional large nucleases SpCas9 and AsCas12a. Therefore, there is a need to develop Cas12f gene editing tools with higher activity and a broader targeting range. Summary of the Invention

[0007] The main objective of this invention is to provide a Cas12f nuclease and its derivative gene editing tools with a wider targeting range, thereby overcoming the shortcomings of existing Cas12f editing tools with a narrow targeting range.

[0008] This invention provides a Cas12f nuclease with a broader targeting range, including single-point mutants or combined mutants of all amino acid residues in the Un1Cas12f1 nuclease; wherein the single-point mutant Un1Cas12f1 is: D143S, L152S, Q244R, N133S, E151V, K129N, G130R, N133C, Q244F, P247Q, S135Y, V137C, H139Y, T203M, S246F, Y140W, G200E, G130Q, S135K, V144C, I158M, E20 One of the following: 6F, E206Q, Q242T, S246A, I131K, S168C, G200R, Q201P, Y202M, K248S, I131R, A134D, S136V, E138Q, R148W, G199F, A134Q, S136P, V137N, Y140A, C145S, R148V, E151W, L152H, K154S, K167H, G199Y, Y202L, K245H, K248I; the combined mutant Un1Cas12f1 is any combination of the above single-point mutants.

[0009] Furthermore, the Cas12f nuclease also includes other mutations or modifications to perform precise editing functions.

[0010] Preferably, the Cas12f nuclease further includes a Q197K mutation or other mutations at the same site, denoted as Cas12f-SSRSVK, the sequence of which is shown in SEQ NO.2. According to conventional knowledge in the art, editing can be achieved by mutating the Q197 residue to other amino acids.

[0011] The present invention also provides an adenine base editor comprising the aforementioned Cas12f-SSRSV or Cas12f-SSRSVK.

[0012] The present invention also provides a cytosine base editor comprising the aforementioned Cas12f-SSRSV or Cas12f-SSRSVK.

[0013] The present invention also provides a transcriptional activation tool comprising the aforementioned Cas12f-SSRSV or Cas12f-SSRSVK.

[0014] Preferably, the above-mentioned nuclease, adenine base editor, cytosine base editor, or transcription activation tool all include a promoter, wherein the promoter is selected from at least one of CMV, CAG, PGK, EF1α, Ctsk (muscle-specific promoter), and Lp (liver-specific promoter).

[0015] Preferably, the above-mentioned nuclease, adenine base editor, cytosine base editor, or transcription activation tool all include a nuclear localization signal (NLS), wherein the NLS is selected as SV40 NLS or bpNLS, or other types of nuclear localization signals.

[0016] Preferably, the above-mentioned nuclease, adenine base editor, cytosine base editor, or transcription activation tool all include polyadenylation (polyA), wherein the polyA is selected from bovine growth hormone polyadenylation signal BGH polyA, or other species including eukaryotic and prokaryotic polyadenylation signals.

[0017] Preferably, the linker used by the adenine base editor, cytosine base editor, or transcription activation tool to connect MCP and effector proteins is the (SGGS)2-XTEN-(SGGS)2 linker, or other types of linkers.

[0018] Preferably, the adenine base editor includes deaminase TadA8e (F148A), wherein the deaminase TadA is selected from Escherichia coli-derived deaminase TadA.

[0019] Preferably, the adenine base editor is SSRSV-ABE, with the composition CMV-SV40 NLS-dUn1Cas12f1(SSRSV)-bpNLS-P2A-SV40 NLS-MCP-32aa linker-TadA8e(F148A)-bpNLS-BGH polyA, as shown in SEQ NO.3. It also includes other permutations and combinations, other Cas12f nucleases with DNA recognition and cutting functions, and other positional changes such as adenine deaminase embedded in the middle of a nuclease.

[0020] Most preferably, the sgRNA of the adenine base editor SSRSV-ABE contains an MS2 hairpin structure, which is inserted into Stem loop 4 and its sequence is shown in SEQ NO.6. This also includes inserting the MS2 hairpin structure into other positions, inserting different numbers of MS2 hairpin structures, or replacing it with a hairpin structure that is compatible with other RNA binding proteins.

[0021] Preferably, the cytosine base editor described above includes deaminase A3A (D131P), wherein the deaminase A3A is selected from human APOBEC3A.

[0022] Preferably, the above-mentioned cytosine base editor is SSRSV-CBE, with the composition CMV-SV40 NLS-dUn1Cas12f1(SSRSV)-bpNLS-P2A-SV40 NLS-MCP-32aa linker-A3A(D131P)-bpNLS-T2A-2xUGI-SV40NLS-BGH polyA, as shown in SEQ NO.4. It also includes other permutations and combinations, other Cas12f nucleases with DNA recognition and cleavage functions, and other positional changes such as cytosine deaminase embedding in the middle of a nuclease.

[0023] Most preferably, the sgRNA of the above-mentioned cytosine base editor SSRSV-CBE contains an MS2 hairpin structure, which is inserted into Stem loop 4 and its sequence is shown in SEQ NO.6. This also includes inserting the MS2 hairpin structure into other positions, inserting different numbers of MS2 hairpin structures, or replacing it with a hairpin structure adapted to other RNA binding proteins.

[0024] Preferably, the transcription activation tool described above includes a transcription activation element, wherein the transcription activation element is P65-HSF1.

[0025] Preferably, the transcription activation tool is PHM-SSRSV, composed of CMV-SV40 NLS-P65-HSF1-32aalinker-MCP-bpNLS-P2A-SV40 NLS-dUn1Cas12f1(SSRSV)-bp NLS-BGH polyA, the sequence of which is shown in SEQ NO.5. Other permutations and combinations are also included, as well as other Cas12f nucleases with DNA recognition and cleavage functions, and other positional changes such as the embedding of transcription activation elements in the middle of nucleases.

[0026] Most preferably, the sgRNA of the adenine base editor SSRSV-ABE contains an MS2 hairpin structure, which is inserted at the 5' end and in Stem loop 2, and its sequence is shown in SEQ NO.7. This also includes inserting the MS2 hairpin structure at other positions, inserting different numbers of MS2 hairpin structures, or replacing it with a hairpin structure adapted to other RNA binding proteins.

[0027] This invention also provides the application of a Cas12f nuclease, adenine base editor, cytosine base editor, or transcription activation tool with a wider targeting range in gene editing.

[0028] Preferably, the nuclease, adenine base editor, and cytosine base editor are used to achieve base editing by plasmid transfection; or by transfection of mRNA, electroporation of proteins; or by delivery of DNA, mRNA, or proteins via nanoliposomes, viruses, or viroids.

[0029] Preferably, the cells for the nuclease, adenine base editor, cytosine base editor, or transcription activation tool are HEK293T cells; or other cells derived from humans and other mammals; or all kinds of animal and plant cells; or other gametes and fertilized eggs derived from humans and other mammals.

[0030] Preferably, the cells used are eukaryotic cells, but non-eukaryotic cells such as prokaryotes and ancient organisms are also included. This also includes cells within animals that can be used for editing, treatment, and gene expression regulation.

[0031] Preferably, the gene editing includes gene therapy, cell therapy, animal model construction, and crop genetic breeding.

[0032] Beneficial effects

[0033] This invention uses a bacterial forward screening system to identify 71 point mutations capable of cleaving NTTR and TNTR PAM. Further screening at endogenous targets in NTTR and TNTR PAM ultimately identified five key point mutations: D143S, L152S, Q244R, N133S, and E151V. This led to the successful development of the Un1Cas12f1 mutant Cas12f-SSRSV, which has a broader targeting range, and its editing characteristics were evaluated. Simultaneously, this invention utilizes the MS2-MCP strategy to construct the adenine base editor SSRSV-ABE, the cytosine base editor SSRSV-CBE, and the transcription activation tool PHM-SSRSV, all with broader targeting ranges. Compared to other Cas12f-related ABEs, SSRSV-ABE has a wider targeting range, higher editing efficiency, and fewer bystander edits, making it a more precise adenine base editor with higher PAM compatibility. Compared to miniCBEs, SSRSV-CBE significantly improves editing efficiency while broadening the targeting range. PHM-SSRSV can enhance the transcription level of endogenous gene mRNA at the NTNR PAM endogenous target. The high PAM compatibility and activity of Cas12f-SSRSV, SSRSV-ABE, SSRSV-CBE, and PHM-SSRSV provide more options for target design. This invention stems from the practical needs of gene editing tools in clinical translation, developing smaller nucleases, ABEs, CBEs, and transcriptional activation tools with higher PAM compatibility, possessing certain clinical translational value. Attached Figure Description

[0034] Figure 1 This is a schematic diagram illustrating the forward filtering principle of the Un1Cas12f1 library.

[0035] Figure 2 Un1Cas12f1 mutants that identify NTTR, TNTR, and PAM in bacteria are used for positive selection.

[0036] Figure 3 Un1Cas12f1 mutants of NTTR, TNTR, and PAM were screened for endogenous targets to identify them.

[0037] Figure 4 To improve the editing efficiency of Cas12f-SSRSV on NTTR, TNTR, and PAM endogenous targets.

[0038] Figure 5 This indicates the preference of Cas12f-SSRSV for the second base of PAM.

[0039] Figure 6 This is a schematic diagram illustrating the principle of GFP expression activation in cell lines.

[0040] Figure 7PAM preference for wild-type Un1Cas12f1 and Cas12f-SSRSV.

[0041] Figure 8 To improve the editing efficiency of Cas12f-SSRSV on endogenous targets in NTNR PAM.

[0042] Figure 9 This is a partial crystal structure diagram of Un1Cas12f1 (PDB: 7C7L).

[0043] Figure 10 Screening for Cas12f-SSRSV mutants for the endogenous target of VVTR PAM.

[0044] Figure 11 This indicates the preference of Cas12f-SSRSVK for the second base of PAM.

[0045] Figure 12 This is a schematic diagram of the MCP-MINI ABE structure.

[0046] Figure 13 The impact of different MCP-MINI ABE structures on editing efficiency.

[0047] Figure 14 This is a diagram illustrating the insertion of the MS2 label.

[0048] Figure 15 The impact of different MS2 tag insertion positions and numbers on editing efficiency.

[0049] Figure 16 The impact of the linker length between MCP and TadA8e on editing efficiency.

[0050] Figure 17 The effects of different TadA8e mutants on the editing window.

[0051] Figure 18 Editing efficiency of SSRSV-ABE at the 293T endogenous target site.

[0052] Figure 19 A comparison of the editing efficiency of four Cas12f-ABE models.

[0053] Figure 20 A comparison of four Cas12f-ABE editing windows.

[0054] Figure 21 A comparison of editing efficiency between miniCBE and SSRSV-CBE.

[0055] Figure 22 This is a schematic diagram illustrating the principle of GFP transcriptional activation in cell lines.

[0056] Figure 23 Optimization of the Cas12f-MPH sgRNA structure.

[0057] Figure 24 This is a schematic diagram of the Cas12f-MPH structure.

[0058] Figure 25 Optimization of the Cas12f-MPH structure.

[0059] Figure 26 The transcriptional activation level of PHM-SSRSV in the HEK293T endogenous gene. Detailed Implementation

[0060] It should be noted that, unless otherwise specified, the embodiments and features described in this application can be combined with each other. The present invention will now be described in detail with reference to the accompanying drawings and embodiments.

[0061] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the protection scope of the present invention.

[0062] It should be noted that the terms "first," "second," etc., in the specification, claims, and accompanying drawings of this invention are used to distinguish similar objects and are not necessarily used to describe a specific order or sequence. It should be understood that such data can be interchanged where appropriate so that the embodiments of the invention described herein can be implemented in orders other than those illustrated or described herein. Furthermore, the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion.

[0063] Example 1

[0064] Based on the crystal structure of Un1Cas12f1 (PDB: 7C7L), 59 amino acids (K129-S168, K196-I207, Q242-K248) close to the PAM double strand were selected to construct a single-point saturation mutant library, and a bacterial forward screening system suitable for Un1Cas12f1 was established. Figure 1 ). A bacterial positive selection system was used to screen for 71 point mutations capable of cleaving NTTR and TNTRPAM. Figure 2 ), and further screening on endogenous targets of NTTR, TNTR, and PAM ( Figure 3Finally, five key mutations, D143S, L152S, Q244R, N133S, and E151V, were selected and superimposed to form Cas12f-SSRSV, the sequence of which is shown in SEQ NO.1.

[0065] The editing efficiency of Cas12f-SSRSV was tested at 24 endogenous target sites of NTTR, TNTR, and PAM. Figure 4 The results showed that the editing efficiency of wild-type Un1Cas12f1 ranged from 2.26% to 53%, while that of Cas12f-SSRSV ranged from 14.79% to 71.41%, representing a 5.2-fold improvement compared to wild-type Un1Cas12f1. In summary, by combining bacterial positive selection and endogenous target selection, a Un1Cas12f1 mutant—Cas12f-SSRSV—capable of recognizing and cleaving NTTR, TNTR, and PAM was developed.

[0066] The study examined whether Cas12f-SSRSV could identify and cleave the intrinsic target of NNTR PAM. Figure 5 Among 40 NNTRPAM endogenous targets, Cas12f-SSRSV improved editing efficiency by an average of 15.4 times compared with wild-type Un1Cas12f1. It was also found that Cas12f-SSRSV may have a certain preference for the second T position.

[0067] Therefore, GFP expression was used to activate the cell line ( Figure 6 The PAM of Cas12f-SSRSV was analyzed. This cell line had a 5bp random sequence inserted after the GFP start codon ATG as the Cas12f PAM, followed by a 24bp target sequence. Because the sum of the inserted PAM and target sequences was not a multiple of 3, GFP was not expressed. However, when transformed into plasmids expressing Cas12f and sgRNA, if Cas12f recognizes the PAM and cleaves the target sequence, resulting in insertion or deletion, the GFP reading frame might be restored, activating GFP expression. GFP-positive cells were sorted and subjected to deep sequencing to detect the Cas12f-recognized PAM. The results showed that (…). Figure 7 The PAM of wild-type Un1Cas12f1 is TTTR, and the second T is very conservative. Although Cas12f-SSRSV significantly reduces the restriction of the second T of Un1Cas12f1, it still has some bias. However, Cas12f-SSRSV has almost no restriction on the first and third T of PAM. Therefore, the PAM of Cas12f-SSRSV is defined as NTNR.

[0068] The editing efficiency of Cas12f-SSRSV was tested at 40 intrinsic target sites of NTNR PAM. Figure 8 The results showed that Cas12f-SSRSV improved editing efficiency by an average of 9.5 times compared with wild-type Un1Cas12f1.

[0069] Further optimization of Cas12f-SSRSV based on crystal structure attempts to eliminate the restriction on the second T position of PAM ( Figure 9 Two amino acid residues, Y146 and Q197, that interact with the second T·A base pair in TTTR PAM were selected. Single-point saturation mutagenesis was performed on these two amino acids, and the mutations were introduced into Cas12f-SSRSV. Screening was then conducted at endogenous targets in VVTR PAM. Figure 10 The introduction of the Q197K mutation significantly improved the editing efficiency of Cas12f-SSRSV at four of the six selected target sites. Therefore, this mutant was named Cas12f-SSRSVK, and its sequence is shown in SEQ NO.2. After testing on a large number of NNTR PAM endogenous target sites, it was found that Cas12f-SSRSVK significantly improved the editing efficiency at NCTR PAM target sites. Figure 11 However, its editing efficiency on the NTTR PAM target is lower than that of Cas12f-SSRSV. Therefore, it is believed that Cas12f-SSRSVK has not eliminated the restriction on the second T position of PAM, but rather prefers the NCTR PAM target.

[0070] Example 2

[0071] Based on the MS2 tag-MCP RNA-binding protein strategy, we developed two Cas12f-related adenine base editors, SSRSV-ABE and SSRSV-CBE, which have a broader targeting range. First, the MS2 tag was fused to the 5' end of the sgRNA, and MCP and TadA8e were fused to the N-terminus or C-terminus of dUn1Cas12f1 in different orders, constructing four MCP-MINI ABEs (…). Figure 12The dUn1Cas12f1 protein is linked to TadA8e or MCP via a P2A self-cleaving peptide. During protein expression, the ribosome skips the formation of the peptide bond between the glycine and proline residues at the P2A A-terminus, without affecting subsequent protein translation. This allows for the separate translation of the N-terminus and C-terminus of the P2A protein, resulting in two independent proteins. Testing was performed on the HEK293T endogenous target site of three TTTR PAMs (Figure 13), and the optimal structure was dUn1Cas12f1-P2A-MCP-TadA8e (C1). Next, the MS2 tag insertion position was optimized by inserting the MS2 tag into different stem-loop structures of the sgRNA (Figure 14). Test results showed that the optimal sgRNA structure was S4-MS2 (…). Figure 15 The length of the linker between MCP and TadA8e was also optimized (Fig. 16). The results showed that different linker lengths had no impact on editing efficiency, but C1 still exhibited high A-to-G editing efficiency at the far end of the PAM. Therefore, a point mutation was introduced into TadA8e to narrow the editing window. Tests on the HEK293T endogenous target sites of three TTTR PAMs revealed (Fig. 17) that the introduction of F148A improved editing efficiency while narrowing the editing window. The polyA polyA of CMV-SV40 NLS-dUn1Cas12f1-bpNLS-P2A-SV40NLS-MCP-32aa linker-TadA8e(F148A)-bpNLS-BGH was named MCP-MINI ABE.

[0072] Example 3

[0073] The SSRSV mutation was introduced into the MCP-MINI ABE to construct the SSRSV-ABE, the sequence of which is shown in SEQ NO.3, and it was tested at the HEK293T endogenous target site. Figure 18 The SSRSSV-ABE achieved an average A-to-G editing efficiency of 17.83% on 12 non-TTTR PAM targets and 28.83% on 5 TTTR PAM targets, representing improvements of 9.73 times and 1.26 times respectively compared to the MCP-MINI ABE. Compared to previously reported Cas12f-ABE systems such as dCasMINI-ABE, TaRGET-C3.1, and miniABE, the SSRSV-ABE demonstrates higher editing efficiency, averaging 25.3% on the 6 tested targets, and features a narrower editing window, primarily concentrated in the A3 and A4 positions. Figure 19 , Figure 20 ).

[0074] By replacing TadA in SSRSV-ABE with cytosine deaminase A3A-D131P and adding UGI, SSRSV-CBE was developed, its sequence of which is shown in SEQ NO.4. Testing at endogenous targets revealed (…). Figure 21 Compared to the previously reported miniCBE, the SSRSV-CBE further improves editing efficiency while expanding PAM.

[0075] Example 4

[0076] The Cas12f-MPH transcriptional activation system was developed using the same MS2-MCP strategy. First, a GFP transcriptional activation cell line was constructed (…). Figure 22 Seven repeats of TTTG PAM and the target sequence were inserted before the TRE3G promoter. If dUn1Cas12f1 binds to the target sequence and recruits MCP-p65-HSF1 to the vicinity of the TRE3G promoter via the MS2 tag on the sgRNA, GFP transcription and expression will be activated. The transcriptional activation efficiency of Cas12f-MPH can be determined by detecting the proportion of GFP-positive cells through flow cytometry.

[0077] A transcriptional activation system was constructed according to the optimal structure C1 of SSRSV-ABE. MCP-p65-HSF1 was linked to the C-terminus of dUn1Cas12f1 via a P2A self-cleaving peptide. MS2 tags were inserted into the 5' end of the sgRNA or onto different stem-loop structures, and the number of MS2 tags was increased. The transcriptional activation efficiency of Cas12f-MPH was then tested. The test results showed that the optimal sgRNA structure was 5'-MS2+S2-MS2 (…). Figure 23 Next, we will continue to optimize the structure of Cas12f-MPH (). Figure 24 Four different working systems were built and tested, and the results showed that ( Figure 25 The optimal transcriptional activation system is CMV-SV40 NLS-P65-HSF1-32aa linker-MCP-bpNLS-P2A-SV40 NLS-dUn1Cas12f1-bp NLS-BGH polyA, which is named PHM-Cas12f.

[0078] A point mutation of SSRSV was introduced into PHM-Cas12f to construct CMV-SV40 NLS-P65-HSF1-32aa linker-MCP-bpNLS-P2A-SV40 NLS-dUn1Cas12f1(SSRSV)-bp NLS-BGH polyA (hereinafter referred to as PHM-SSRSV), the sequence of which is shown in SEQ NO.5. This was intended to expand the targeting range of PHM-Cas12f, and tests were performed on six HEK293T endogenous target sites. The results are as follows: Figure 26 As shown, PHM-SSRSV exhibited higher transcriptional activation levels at all six target sites than PHM-Cas12f. Compared to untreated cells, PHM-SSRSV-treated cells showed a 66-4734-fold increase in the relative expression level of target gene mRNA, while PHM-Cas12f-treated cells showed a 3.85-681-fold increase. These results indicate that, compared to PHM-Cas12f, PHM-SSRSV not only broadens the target range but also further enhances transcriptional activation levels.

[0079] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A Cas12f nuclease with a broader targeting range, said nuclease being Cas12f-SSRSV, characterized in that, It is encoded by the nucleotide sequence shown in SEQ NO.

1.

2. The Cas12f nuclease according to claim 1, wherein the nuclease is Cas12f-SSRSVK, characterized in that, It is encoded by the nucleotide sequence shown in SEQ NO.

2.

3. An adenine base editor, characterized in that, The Cas12f nuclease of claim 1 includes an inactivated form.

4. A cytosine base editor, characterized in that, The Cas12f nuclease of claim 1 includes an inactivated form.

5. A transcription activation tool, characterized in that, The Cas12f nuclease of claim 1 includes an inactivated form.

6. The adenine base editor according to claim 3, the cytosine base editor according to claim 4, or the transcription activation tool according to claim 5, characterized in that: The linker used to connect MCP and effector proteins is (SGGS)2-XTEN-(SGGS)2, which is 32 amino acids in length.

7. The adenine base editor according to claim 3, characterized in that: The connection sequence between adenine deaminase, dCas12f, MCP, nuclear localization signal and linker that constitute ABE is arranged in a different order.

8. The adenine base editor according to claim 3, characterized in that: All ABE sgRNAs contain the MS2 hairpin structure, which is inserted into Stem loop 4.

9. The cytosine base editor according to claim 4, characterized in that: The connection sequence between cytosine deaminase, UGI, dCas12f, MCP, nuclear localization signal and linker that constitute CBE is arranged in different orders.

10. The cytosine base editor according to claim 4, characterized in that: All CBE sgRNAs contain the MS2 hairpin structure, which is inserted into Stem loop 4.

11. The transcription activation tool according to claim 5, characterized in that: It includes a transcriptional activation element, wherein the transcriptional activation element is P65-HSF1.

12. The transcription activation tool according to claim 5, characterized in that: The connection order between the transcriptional activation element P65, the transcriptional activation element HSF1, dCas12f, MCP, nuclear localization signal and linker that constitute the transcriptional activation tool is arranged in different orders.

Citation Information

Patent Citations

  • Adenine deaminase, adenine base editor containing adenine deaminase and application of adenine base editor

    CN115772512A

  • Miniature base editor and construction method and application thereof

    CN118086340A